RDPTF
Radiopharm Theranostics Limited
Price Chart
Latest Quote
$0.02
+0.00 (+0.00%)
Current Price
| Previous Close | $0.02 |
| Open | $0.02 |
| Day High | $0.02 |
| Day Low | $0.02 |
| Volume | 25,000 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 2.36B |
| Cash Equivalents | $24.40M |
| Revenue | $11.51M |
| Net Income | $-32.93M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $47.30M |
| EPS (TTM) | $-0.01 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $34.53M |
| Sales | $11.51M |
| Income | $-32.93M |
| Book/sh | $0.01 |
| Cash/sh | $0.01 |
| Employees | 14 |
Financial Ratios
| Quick Ratio | 3.00 |
| Current Ratio | 3.01 |
Returns & Margins
| ROA | -28.33% |
| ROE | -92.10% |
| Gross Margin | -136.51% |
| Operating Margin | -423.75% |
| Profit Margin | -286.16% |
Ownership
| Insider Ownership | 28.09% |
| Institutional Ownership | 11.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 2.91 |
| P/B | 1.87 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.02 |
| SMA50 | $0.02 |
| SMA200 | $0.02 |
| RSI | nan |
| Shares Float | 2.49B |
| Volatility | 0.80 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | +0.00% |
| 6 Months | +0.00% |
| YTD | +0.00% |
| Year | +76.99% |
| 3 Years | -77.78% |
| 10 Years | -77.78% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-16 | $0.02 | 0 |
| 2026-06-15 | $0.02 | 0 |
| 2026-06-12 | $0.02 | 0 |
| 2026-06-11 | $0.02 | 0 |
| 2026-06-10 | $0.02 | 0 |
| 2026-06-09 | $0.02 | 0 |
| 2026-06-08 | $0.02 | 0 |
| 2026-06-05 | $0.02 | 0 |
| 2026-06-04 | $0.02 | 0 |
| 2026-06-03 | $0.02 | 0 |
| 2026-06-02 | $0.02 | 0 |
| 2026-06-01 | $0.02 | 0 |
| 2026-05-29 | $0.02 | 0 |
| 2026-05-28 | $0.02 | 0 |
| 2026-05-27 | $0.02 | 0 |
| 2026-05-26 | $0.02 | 0 |
| 2026-05-22 | $0.02 | 0 |
| 2026-05-21 | $0.02 | 0 |
| 2026-05-20 | $0.02 | 0 |
| 2026-05-19 | $0.02 | 0 |
| 2026-05-18 | $0.02 | 0 |
About Radiopharm Theranostics Limited
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are AvÃ6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPÂĩ glioblastoma diagnostic; and RAD602, a PTPÂĩ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.
đ° Latest News
Radiopharm Theranostics Highlights Phase 1 Pipeline, Eyes June RAD 101 Data at DB Conference
MarketBeat âĸ 2026-04-29T09:04:38Z
Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs
Insider Monkey âĸ 2026-04-28T17:29:48Z
Inside Biotech: Radiopharm advances RAD 402 into clinic with first patient dosed in Phase 1 trial
Proactive âĸ 2026-03-26T23:20:00Z
Radiopharm Theranostics Shares RAD101 Phase IIb Update: 90% Hit Primary Endpoint in Brain Mets Study
MarketBeat âĸ 2026-03-25T08:32:23Z
Radiopharm Theranostics Highlights 90% Positive RAD101 Interim Data, Eyes Phase III FDA Talks
MarketBeat âĸ 2026-03-25T07:33:01Z
Favourable Signals For Radiopharm Theranostics: Numerous Insiders Acquired Stock
Simply Wall St. âĸ 2025-12-22T00:57:27Z
Radiopharm (RADX) Sees Slight Pessimism From Analysts
Insider Monkey âĸ 2025-12-15T17:35:45Z
Top Midday Gainers
MT Newswires âĸ 2025-12-15T17:28:27ZRadiopharm Theranostics Expects to Raise $22.7 Million Via Private Placement, Shares Down Pre-Bell
MT Newswires âĸ 2025-10-20T12:23:51ZRadiopharm receives DSMC recommendation to advance Phase 1 âHEATâ trial
TipRanks âĸ 2025-10-02T12:15:46Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $3,594,146 | $0 | $0 | - |
| Cost Of Revenue | $3,594,146 | $0 | $0 | - |
| Total Revenue | $3,633,422 | $299,228 | $292,359 | $8,831 |
| Operating Revenue | $3,633,422 | $299,228 | $292,359 | $8,831 |
| Expenses | ||||
| Interest Expense | $65,300 | $642,888 | $86,091 | $9,349,739 |
| Total Expenses | $38,274,157 | $37,473,113 | $31,982,960 | $19,925,183 |
| Other Income Expense | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Net Non Operating Interest Income Expense | $333,109 | $-225,685 | $58,944 | $-9,349,739 |
| Total Other Finance Cost | $489,787 | $-366,719 | - | - |
| Interest Expense Non Operating | $65,300 | $642,888 | $86,091 | $9,349,739 |
| Operating Expense | $34,680,011 | $37,473,113 | $31,982,960 | $19,925,183 |
| Other Operating Expenses | $-9,368,544 | $-1,292,578 | $-5,917,484 | $1,606,799 |
| General And Administrative Expense | $16,526,030 | $15,671,890 | $15,262,382 | $11,212,148 |
| Other Non Operating Income Expenses | - | $-7,567,780 | $5,917,484 | $-1,028,491 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Interest Income | $333,109 | $-225,685 | $58,944 | $-9,349,739 |
| Interest Income | $888,196 | $50,484 | $145,035 | - |
| Normalized Income | $-35,590,380 | $-40,631,890 | $-32,552,122 | $-29,619,035 |
| Net Income From Continuing And Discontinued Operation | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Total Operating Income As Reported | $-38,173,865 | $-47,209,867 | $-34,487,098 | - |
| Net Income Common Stockholders | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income Including Noncontrolling Interests | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Net Income Continuous Operations | $-38,342,457 | $-47,949,119 | $-34,611,194 | $-30,338,979 |
| Pretax Income | $-38,239,165 | $-47,852,755 | $-34,573,189 | $-30,294,582 |
| Special Income Charges | $-4,069,680 | $-10,548,149 | $-2,684,281 | - |
| Interest Income Non Operating | $888,196 | $50,484 | $145,035 | - |
| Operating Income | $-34,640,735 | $-37,173,885 | $-31,690,601 | $-19,916,352 |
| Depreciation Amortization Depletion Income Statement | $7,331 | $7,534 | $6,553 | $2,981,484 |
| Depreciation And Amortization In Income Statement | $7,331 | $7,534 | $6,553 | $2,981,484 |
| Depreciation Income Statement | $7,331 | $7,534 | $6,553 | $1,171 |
| Gross Profit | $39,276 | $299,228 | $292,359 | $8,831 |
| Amortization Of Intangibles Income Statement | - | $3,118,752 | $3,289,979 | $2,980,313 |
| Per Share | ||||
| Diluted EPS | $-0.02 | $-0.12 | $-0.11 | $-0.15 |
| Basic EPS | $-0.02 | $-0.12 | $-0.11 | $-0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,179,462 | $-3,135,956 | $-882,460 | $-308,547 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-34,234,995 | $-36,749,148 | $-31,539,013 | $-16,934,868 |
| Total Unusual Items | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Total Unusual Items Excluding Goodwill | $-3,931,539 | $-10,453,185 | $-2,941,532 | $-1,028,491 |
| Reconciled Depreciation | $7,331 | $7,534 | $6,553 | $2,981,484 |
| EBITDA (Bullshit earnings) | $-38,166,534 | $-47,202,333 | $-34,480,545 | $-17,963,359 |
| EBIT | $-38,173,865 | $-47,209,867 | $-34,487,098 | $-20,944,843 |
| Diluted Average Shares | $2,085,402,784 | $386,460,137 | $323,816,539 | $198,514,296 |
| Basic Average Shares | $2,081,058,451 | $386,460,137 | $323,816,539 | $198,514,296 |
| Diluted NI Availto Com Stockholders | $-38,342,457 | $-47,949,119 | $-34,611,194 | - |
| Tax Provision | $103,292 | $96,364 | $38,005 | $44,397 |
| Gain On Sale Of Ppe | $0 | $-1,687,791 | $0 | - |
| Restructuring And Mergern Acquisition | $4,069,680 | $8,860,358 | $2,684,281 | - |
| Gain On Sale Of Security | $138,141 | $94,964 | $-257,251 | $-1,028,491 |
| Research And Development | $27,515,194 | $23,086,267 | $22,631,509 | $4,124,752 |
| Selling General And Administration | $16,526,030 | $15,671,890 | $15,262,382 | $11,212,148 |
| Other Gand A | $4,404,771 | $3,223,724 | $5,389,768 | $1,969,617 |
| Insurance And Claims | $105,762 | $359,209 | $685,413 | - |
| Salaries And Wages | $12,015,497 | $12,088,957 | $9,187,201 | $9,242,531 |
| Impairment Of Capital Assets | - | $1,478,892 | $3,100,000 | - |
| Amortization | - | $3,118,752 | $3,289,979 | $2,980,313 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,782,418 | $-20,964,726 | $-14,156,746 | $6,887,411 |
| Total Assets | $86,481,876 | $72,036,345 | $74,949,668 | $83,381,291 |
| Total Non Current Assets | $46,627,888 | $49,188,085 | $58,649,564 | $56,116,886 |
| Investmentin Financial Assets | $0 | $40,000 | - | - |
| Goodwill And Other Intangible Assets | $46,574,422 | $49,087,288 | $58,541,234 | $56,075,308 |
| Other Intangible Assets | $46,574,422 | $49,087,288 | $58,541,234 | $56,075,308 |
| Current Assets | $39,853,988 | $22,848,260 | $16,300,104 | $27,264,405 |
| Other Current Assets | $337,093 | $288,215 | $133,130 | $228,818 |
| Assets Held For Sale Current | $0 | $2,997,592 | - | - |
| Receivables | $10,400,060 | $987,413 | $4,467,908 | $56,482 |
| Other Receivables | $228,528 | $184,425 | $4,363,200 | - |
| Taxes Receivable | $10,171,532 | $802,988 | - | - |
| Cash Cash Equivalents And Short Term Investments | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Cash And Cash Equivalents | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Cash Financial | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Other Non Current Assets | - | $40,000 | $40,000 | $40,000 |
| Accounts Receivable | - | $802,988 | $104,708 | $56,482 |
| Gross Accounts Receivable | - | $802,988 | $104,708 | $56,482 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $43,609,972 | $44,683,059 | $29,370,243 | $20,418,572 |
| Total Non Current Liabilities Net Minority Interest | $28,676,987 | $27,107,289 | $16,141,046 | $12,539,945 |
| Other Non Current Liabilities | $28,676,987 | $27,107,289 | $15,971,844 | $12,387,498 |
| Tradeand Other Payables Non Current | $0 | $0 | $169,202 | $152,447 |
| Non Current Deferred Liabilities | $0 | $0 | - | - |
| Current Liabilities | $14,932,985 | $17,575,770 | $13,229,197 | $7,878,627 |
| Other Current Liabilities | $3,421,337 | $3,963,305 | $7,820,702 | $5,632,168 |
| Current Deferred Liabilities | $1,720,551 | $2,355,884 | - | - |
| Payables And Accrued Expenses | $9,340,993 | $10,856,793 | $5,119,465 | $2,153,318 |
| Payables | $6,590,331 | $9,176,351 | $5,119,465 | $2,153,318 |
| Other Payable | $242,934 | $2,741,827 | $2,162,937 | $963,678 |
| Accounts Payable | $6,347,397 | $6,434,524 | $2,956,528 | $1,189,640 |
| Equity | ||||
| Common Stock Equity | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Total Equity Gross Minority Interest | $42,871,904 | $27,353,286 | $45,579,425 | $62,962,719 |
| Stockholders Equity | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Other Equity Interest | $849,544 | $849,544 | $2,146,566 | - |
| Gains Losses Not Affecting Retained Earnings | $13,116,919 | $37,930,072 | $10,361,457 | $7,028,105 |
| Other Equity Adjustments | $13,116,919 | $37,930,072 | $10,361,457 | $7,028,105 |
| Retained Earnings | $-145,732,952 | $-111,338,770 | $-65,353,864 | $-30,824,169 |
| Other | ||||
| Ordinary Shares Number | $2,364,949,502 | $460,367,051 | $359,265,292 | $279,769,546 |
| Share Issued | $2,364,949,502 | $460,367,051 | $359,265,292 | $279,769,546 |
| Tangible Book Value | $-1,782,418 | $-20,964,726 | $-14,156,746 | $6,887,411 |
| Invested Capital | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Working Capital | $24,921,003 | $5,272,490 | $3,070,907 | $19,385,778 |
| Total Capitalization | $44,792,004 | $28,122,562 | $44,384,488 | $62,962,719 |
| Minority Interest | $-1,920,100 | $-769,276 | $1,194,937 | - |
| Capital Stock | $176,558,493 | $100,681,716 | $97,230,329 | $86,758,783 |
| Common Stock | $176,558,493 | $100,681,716 | $97,230,329 | $86,758,783 |
| Current Deferred Revenue | $1,720,551 | $0 | - | - |
| Pensionand Other Post Retirement Benefit Plans Current | $450,104 | $399,788 | $289,030 | $93,141 |
| Current Accrued Expenses | $2,750,662 | $1,680,442 | - | - |
| Investments And Advances | $0 | $40,000 | - | - |
| Net PPE | $53,466 | $60,797 | $68,330 | $1,578 |
| Foreign Currency Translation Adjustments | - | $-544,337 | - | - |
| Available For Sale Securities | - | $40,000 | - | - |
| Gross PPE | - | $60,797 | $68,330 | $1,578 |
| Machinery Furniture Equipment | - | $60,797 | $68,330 | $1,578 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-36,645,477 | $-22,975,935 | $-24,732,479 | $-38,254,304 |
| Operating Activities | ||||
| Cash Flowsfromusedin Operating Activities Direct | $-36,645,477 | $-22,975,935 | $-23,201,798 | $-9,915,654 |
| Classesof Cash Receiptsfrom Operating Activities | $5,353,973 | $5,112,301 | $1,847,555 | $-9,915,654 |
| Other Cash Paymentsfrom Operating Activities | - | $4,851,839 | $1,555,196 | - |
| Other Cash Receiptsfrom Operating Activities | - | $4,851,839 | $1,555,196 | - |
| Investing Activities | ||||
| Investing Cash Flow | $1,770,598 | $-320,000 | $-1,530,681 | $-28,369,819 |
| Cash Flow From Continuing Investing Activities | $1,770,598 | $-320,000 | $-1,530,681 | $-28,369,819 |
| Net Other Investing Changes | $-1,226,994 | $-320,000 | - | $-40,000 |
| Capital Expenditure | - | - | $-1,530,681 | $-28,338,650 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Financing Cash Flow | $45,431,548 | $30,196,945 | $9,217,791 | $65,110,114 |
| Cash Flow From Continuing Financing Activities | $45,431,548 | $30,196,945 | $9,217,791 | $65,110,114 |
| Net Other Financing Charges | $-6,646,354 | $-1,650,771 | $-854,764 | $-4,830,886 |
| Net Common Stock Issuance | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Common Stock Issuance | $53,977,902 | $29,645,526 | $10,072,555 | $70,000,000 |
| Repurchase Of Capital Stock | - | $-1,533,771 | $-854,764 | $-4,830,886 |
| Other | ||||
| Repayment Of Debt | $-1,900,000 | $-5,167,000 | $0 | $-69,000 |
| Issuance Of Debt | $0 | $7,369,190 | $0 | $10,000 |
| End Cash Position | $29,116,835 | $18,575,040 | $11,699,066 | $26,979,105 |
| Beginning Cash Position | $18,575,040 | $11,699,066 | $26,979,105 | $27,091 |
| Effect Of Exchange Rate Changes | $-14,874 | $-25,036 | $234,649 | $127,373 |
| Changes In Cash | $10,556,669 | $6,901,010 | $-15,514,688 | $26,824,641 |
| Net Issuance Payments Of Debt | $-1,900,000 | $2,202,190 | $0 | $-59,000 |
| Net Long Term Debt Issuance | $-1,900,000 | $2,202,190 | $0 | $-59,000 |
| Long Term Debt Payments | $-1,900,000 | $-5,167,000 | $0 | $-69,000 |
| Long Term Debt Issuance | $0 | $7,369,190 | $0 | $10,000 |
| Net Intangibles Purchase And Sale | $2,997,592 | $0 | $-1,485,375 | $-28,335,901 |
| Net PPE Purchase And Sale | $0 | $0 | $-45,306 | $-2,749 |
| Purchase Of PPE | $0 | $0 | $-45,306 | $-2,749 |
| Taxes Refund Paid Direct | $0 | $4,851,839 | $1,555,196 | - |
| Interest Received Direct | $800,309 | $50,484 | $145,035 | - |
| Classesof Cash Payments | $-42,799,759 | $-28,138,720 | $-25,194,388 | - |
| Paymentsto Suppliersfor Goodsand Services | $-42,799,759 | $-28,138,720 | $-25,194,388 | - |
| Receiptsfrom Customers | $5,353,973 | $260,462 | $292,359 | $-9,915,654 |
| Common Stock Payments | - | $-1,533,771 | $-854,764 | $-4,830,886 |
| Purchase Of Intangibles | - | - | $-1,485,375 | $-28,335,901 |
| Interest Received Cfi | - | - | - | $8,831 |
Fetched: 2026-02-02